Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.

[1]  D. Neuberg,et al.  Biophysical Determinants for Cellular Uptake of Hydrocarbon-Stapled Peptide Helices , 2016, Nature chemical biology.

[2]  E. Olejniczak,et al.  Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. , 2016, Journal of medicinal chemistry.

[3]  Nibedita Bandyopadhyay,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[4]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[5]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[6]  L. Walensky,et al.  Cellular Uptake and Ultrastructural Localization Underlie the Pro-apoptotic Activity of a Hydrocarbon-stapled BIM BH3 Peptide. , 2015, ACS chemical biology.

[7]  G. Dewson.  Investigating Bax subcellular localization and membrane integration. , 2015, Cold Spring Harbor protocols.

[8]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[9]  Dylan J. Taatjes,et al.  The Mediator complex: a central integrator of transcription , 2015, Nature Reviews Molecular Cell Biology.

[10]  M. Cragg,et al.  Role of the pro-survival molecule Bfl-1 in melanoma. , 2015, The international journal of biochemistry & cell biology.

[11]  C. Tse,et al.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) , 2015, Cell Death and Disease.

[12]  L. Walensky,et al.  Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.

[13]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[14]  L. Walensky,et al.  Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. , 2013, Chemistry & biology.

[15]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[16]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[17]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[18]  D. Proia,et al.  Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib , 2012, Molecular Cancer Therapeutics.

[19]  Evripidis Gavathiotis,et al.  A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.

[20]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[21]  L. Walensky,et al.  Chemical Synthesis of Hydrocarbon‐Stapled Peptides for Protein Interaction Research and Therapeutic Targeting , 2011, Current protocols in chemical biology.

[22]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[23]  L. Walensky,et al.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX. , 2010, Molecular cell.

[24]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[25]  John Calvin Reed,et al.  A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy , 2010, Cell Death and Disease.

[26]  Y. Ron,et al.  Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. , 2010, Blood.

[27]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[28]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[29]  Boguslaw Stec,et al.  The Fas/FADD death domain complex structure unravels signaling by receptor clustering , 2008, Nature.

[30]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[31]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[32]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[33]  S. Eschrich,et al.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis , 2008, BMC Medical Genomics.

[34]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[35]  S. Korsmeyer,et al.  A stapled BID BH3 helix directly binds and activates BAX. , 2006, Molecular cell.

[36]  H. Kajiho,et al.  Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation , 2006, The EMBO journal.

[37]  T. Grogan,et al.  Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures , 2005, Molecular Cancer Therapeutics.

[38]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[39]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[40]  O. Nureki,et al.  A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase , 2004, Nature Structural &Molecular Biology.

[41]  Andre Hoelz,et al.  Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS , 2003, Cell.

[42]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[43]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[44]  F. Bernal,et al.  Dissection of the BCL-2 family signaling network with stabilized alpha-helices of BCL-2 domains. , 2008, Methods in enzymology.

[45]  F. Bernal,et al.  Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains. , 2008, Methods in enzymology.